Esophageal gastrointestinal stromal tumor (GIST) is a mesenchymal tumor originating from interstitial cells of Cajal. Only 1-3% of all GI GISTs occur in the esophagus, most commonly in the distal third. KIT (CD117) or PDGFRA gene mutations are pathognomonic. Due to submucosal origin, it shows right angle sign on barium and well-circumscribed enhancing mass on CT. Immunohistochemistry (c-KIT positivity) is mandatory for differentiation from leiomyoma. Size >2 cm and mitotic index determine malignancy risk. Imatinib therapy has been groundbreaking for KIT-mutant GISTs. Treatment response is assessed using density change (Choi criteria) rather than size alone.
Age Range
40-70
Peak Age
55
Gender
Equal
Prevalence
Rare
GIST originates from interstitial cells of Cajal, the pacemaker cells of the gastrointestinal system, or from common progenitor cells. Activating mutations in the KIT receptor tyrosine kinase gene (most commonly exon 11, 70%) or PDGFRA mutation (5-8%) constitutively activate the signaling pathway controlling cell proliferation, leading to uncontrolled cell growth. In the esophagus, Cajal cells are located between muscularis propria and muscularis mucosae, so the tumor grows from these layers exhibiting a submucosal growth pattern — the mucosa therefore remains usually intact and endoscopic detection can be difficult. Tumor neovascularity is reflected as heterogeneous enhancement on CT, while central blood supply insufficiency due to rapid growth creates necrosis areas — this is the fundamental cause of heterogeneous appearance on CT. Unlike leiomyoma, GIST's myxoid stroma contains mucopolysaccharide-rich extracellular matrix that retains free water — hence producing hyperintense signal on MR T2 (leiomyoma's smooth muscle fibers show short T2). Imatinib selectively inhibits the mutant KIT receptor, inducing apoptosis in tumor cells; post-treatment tumor size may not change but density decreases with increased necrosis — treatment response is therefore evaluated by Choi criteria instead of RECIST.
Esophageal submucosal mass showing hyperintense signal on MRI T2. Most valuable non-invasive finding for differentiating from leiomyoma (T2 low signal). Reflects the free water content of myxoid stroma. Leiomyoma's smooth muscle fibers give short T2 — this fundamental physics difference plays a critical role in preoperative characterization of esophageal submucosal tumors.
Heterogeneously enhancing submucosal mass in the esophageal wall on CT. Solid components enhance intensely in arterial phase while central necrosis or cystic degeneration areas do not enhance. Size is usually larger than leiomyoma (>5 cm) and exophytic growth pattern may be present. The mass has well-defined margins relative to surrounding tissues, but mediastinal fat planes may be obliterated in large tumors.
Report Sentence
Heterogeneously enhancing submucosal mass measuring approximately ___ cm in the esophageal wall with intensely enhancing solid components and central areas of low density consistent with necrosis; GIST should be the primary consideration.
Submucosal mass showing intermediate-to-high signal on T2-weighted sequence. Myxoid stroma areas appear markedly hyperintense. Necrotic areas show very high T2 signal. This signal characteristic is the most critical non-invasive finding for differentiating from leiomyoma (T2 low signal). The tumor may be homogeneous or heterogeneous — heterogeneity increases proportionally with size and amount of necrosis.
Report Sentence
Hyperintense signal on T2 in the esophageal submucosal mass, suggesting GIST with myxoid stroma content rather than leiomyoma.
GISTs show variable diffusion restriction on diffusion-weighted imaging. High cellularity (aggressive) GISTs show marked diffusion restriction and low ADC values, while low-risk GISTs may show free diffusion. Necrotic areas show T2 shine-through effect — ADC map must be evaluated to differentiate from true restriction. The degree of DWI restriction correlates with mitotic activity and malignancy risk.
Report Sentence
Diffusion restriction on DWI with low signal on ADC map in the esophageal submucosal mass, suggesting high cellularity.
GIST may show exophytic growth from the esophageal wall — the mass extends into the mediastinum or abdominal cavity. The intraluminal component may be small while the exophytic component is large ('iceberg' phenomenon). This pattern makes endoscopic detection difficult. CT's cross-sectional imaging capability reveals the true size and relationship with surrounding structures. Exophytic growth is more common in GIST than leiomyoma.
Report Sentence
Mass showing exophytic extension from the esophageal wall into the mediastinum with small intraluminal and dominant exophytic component; consistent with GIST.
FDG uptake in GISTs correlates with tumor biological aggressiveness. High mitotic activity (aggressive) GISTs show prominent FDG uptake (SUVmax generally >5), while low-risk GISTs may show low uptake or be FDG-negative. PET-CT is the gold standard for early treatment response assessment — SUV decrease 1-2 weeks after imatinib initiation is detected before morphological changes. In metastatic disease (liver, peritoneum), both primary and metastatic lesions are evaluated.
Report Sentence
Prominent FDG uptake with SUVmax ___ in the esophageal mass consistent with metabolically active tumor; high-risk GIST should be considered.
Hypoechoic mass connected to muscularis propria (4th layer) on endoscopic ultrasonography (EUS). GIST typically appears homogeneously or heterogeneously hypoechoic — heterogeneity reflects necrosis or cystic degeneration. The mass is well-circumscribed with intact mucosa (layers 1-3). Size >2 cm, irregular borders, cystic areas, and echogenic foci are high-risk indicators. EUS-guided fine needle aspiration (FNA) or core biopsy can provide histopathological diagnosis.
Report Sentence
Hypoechoic submucosal mass measuring ___ cm showing continuity with muscularis propria (4th layer) on EUS; consistent with GIST, EUS-guided biopsy recommended.
Liver and peritoneal metastases are the most common distant spread sites in malignant GIST (lymphatic metastasis is rare — an important difference from other GI cancers). Liver metastases may be hypervascular (prominent enhancement in arterial phase) or have cystic/necrotic appearance. Metastases are generally hypodense in portal venous phase. With treatment (imatinib), density decrease without size change is observed in metastases — 'internal necrosis' pattern.
Report Sentence
Multiple hypervascular/hypodense lesions in the liver; in the context of known esophageal GIST, consistent with metastasis.
On T1-weighted sequence, GIST typically shows iso- or slightly hypointense signal relative to muscle tissue. If hemorrhagic component is present, T1 hyperintense foci may be seen — this finding suggests subacute hemorrhage. On contrast-enhanced T1, heterogeneous enhancement is observed; solid components enhance prominently while necrotic/cystic areas do not enhance. Gadolinium-enhanced dynamic MRI reveals the tumor's vascularity pattern and enhancement kinetics.
Report Sentence
Isointense signal to muscle on T1 and heterogeneous enhancement on contrast-enhanced sequence in the esophageal submucosal mass; prominent enhancement of solid components consistent with GIST.
Criteria
Size <5 cm AND mitotic index <5/50 HPF. Covers very low risk (<2 cm, <5/50) and low risk (2-5 cm, <5/50) categories in Fletcher risk classification.
Distinct Features
Homogeneous enhancement on CT, no or minimal necrosis. Homogeneous hyperintense on MR T2. Low or no FDG uptake. Adjuvant imatinib may not be needed after surgery. 5-year recurrence risk <5%. Overlap with benign leiomyoma on imaging is maximal — differentiation frequently requires immunohistochemistry.
Criteria
Size 5-10 cm AND mitotic index <5/50 HPF OR size <5 cm AND mitotic index 6-10/50 HPF. Organ location modifies risk — esophageal GIST has higher malignancy potential than gastric GIST.
Distinct Features
Mildly heterogeneous enhancement on CT, minimal necrosis may be present. Moderate FDG uptake. 3-year adjuvant imatinib should be considered. 5-year recurrence risk 15-25%. CT follow-up generally recommended at 6-month intervals for 5 years.
Criteria
Size >10 cm OR mitotic index >10/50 HPF OR size >5 cm AND mitotic index >5/50 HPF. Rupture (spontaneous or surgical) risk automatically elevates to high risk.
Distinct Features
Markedly heterogeneous enhancement on CT, necrosis present, cystic degeneration may occur. High FDG uptake (SUVmax generally >5). Adjuvant imatinib mandatory (minimum 3 years, lifelong debated). 5-year recurrence risk >50%. Metastasis commonly occurs to liver and peritoneum.
Criteria
KIT (CD117) immunohistochemical staining negative, PDGFRA mutation positive (5-8%). DOG1 immunohistochemistry is used as an adjunct to KIT for confirming GIST diagnosis.
Distinct Features
Epithelioid morphology more common. D842V mutation is imatinib-resistant — avapritinib is effective alternative. Usually located in stomach (very rare in esophagus). Imaging findings indistinguishable from KIT-positive GIST — diagnosis is made by molecular pathology.
Distinguishing Feature
Leiomyoma shows low signal on T2 (tightly packed smooth muscle fibers) and is usually homogeneous; GIST is hyperintense on T2 (myxoid stroma) and may be heterogeneous. Leiomyoma is generally smaller (<5 cm), necrosis is rare, and it does not respond to imatinib (KIT negative). Definitive differentiation is made by immunohistochemistry (c-KIT/CD117/DOG1).
Distinguishing Feature
Schwannoma enhances more homogeneously and is encapsulated; GIST may be heterogeneous and may not show capsule. Schwannoma is S-100 positive and c-KIT negative, GIST is c-KIT positive and S-100 negative. Both can be T2 hyperintense but schwannoma may show target sign.
Distinguishing Feature
SCC shows mucosal destruction and irregular borders — luminal narrowing is prominent; GIST is submucosal with intact mucosa, right angle sign present, and luminal narrowing less prominent. SCC metastasizes lymphatically (regional LAP common); GIST rarely spreads lymphatically (hematogenous — liver, peritoneum).
Distinguishing Feature
Duplication cyst has fluid density (0-20 HU) and does not enhance — wall is thin and smooth; GIST is a solid mass that enhances. Duplication cyst is very hyperintense on T2 (fluid signal), low signal on T1; GIST is intermediate-to-high on T2 and isointense to muscle on T1. Duplication cyst is congenital and usually asymptomatic.
Distinguishing Feature
Lymphoma typically shows diffuse concentric wall thickening with homogeneous enhancement; GIST appears as focal submucosal mass and may be heterogeneous. Lymphoma more commonly accompanies lymphadenopathy. On EUS, lymphoma shows hypoechoic infiltration originating from layers 2-3 while GIST originates from 4th layer (muscularis propria).
Urgency
urgentManagement
surgicalBiopsy
NeededFollow-up
specialist-referralEsophageal GIST is rare but potentially aggressive. GIST possibility should be considered in all esophageal submucosal lesions, and histopathological and immunohistochemical diagnosis (c-KIT/CD117/DOG1) should be established by EUS-guided biopsy. Treatment is planned according to size and risk classification: low-risk lesions (<2 cm) can be observed, intermediate-to-high risk lesions require surgical resection. In high-risk cases, 3+ years of adjuvant imatinib is standard treatment. Treatment response is assessed by Choi criteria. When imatinib resistance develops, sunitinib (2nd line) and regorafenib (3rd line) are available options. Avapritinib has become first-line for PDGFRA D842V-mutant cases.
Treatment of esophageal GIST is surgical resection. Imatinib (tyrosine kinase inhibitor) is used as neoadjuvant or adjuvant therapy. Mitotic count and tumor size determine risk stratification. KIT mutation analysis is important for predicting treatment response.